Iv%25252520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It exerts profound anti-inflammatory and immunosuppressive effects. ## Primary Indications * Cerebral edema (associated with brain tumors, neurosurgery, or abscess). * Refractory shock or septic shock (in select patients). * Acute airway edema (e.g., croup, post-extubation). * Treatment of moderate-to-severe COVID-19. * Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting (CINV). * Exacerbations of asthma or COPD. ## Adult Dosing * **Cerebral Edema:** Initial 10 mg IV, followed by 4 mg IM/IV every 6 hours. * **COVID-19:** 6 mg IV once daily for up to 10 days. * **CINV Prophylaxis:** 8–20 mg IV once before chemotherapy. * **Acute Airway/Laryngeal Edema:** 4–10 mg IV as a single dose. * **Anti-inflammatory/Immunosuppressive:** 0.5–9 mg daily, divided every 6–12 hours (dose highly protocol-dependent). ## Pediatric Dosing * **Croup:** 0.6 mg/kg IV/IM as a single dose (max 10 mg). * **Cerebral Edema:** Initial 1–2 mg/kg IV loading dose, followed by 1–1.5 mg/kg/day divided every 4–6 hours (max dose depends on indication—verify with local institutional protocol). * **Antiemetic:** 0.15–0.5 mg/kg (max 16 mg) IV as a single dose. * **Anti-inflammatory:** 0.08–0.3 mg/kg/day divided every 6–12 hours. ## Dose Adjustments * **Hepatic Impairment:** Clearance may be decreased; use with caution and monitor for increased toxicity. * **Renal Impairment:** No specific adjustment required. * **Special Note:** Chronic therapy requires slow tapering to prevent acute adrenal insufficiency. ## Contraindications * Systemic fungal infections. * Known hypersensitivity to dexamethasone or components of the formulation. * Administration of live or live-attenuated vaccines while on immunosuppressive doses. ## Adverse Effects * **Metabolic:** Hyperglycemia (common), fluid retention, hypokalemia. * **Psychiatric/Neurologic:** Insomnia, agitation, mood swings, psychosis. * **Gastrointestinal:** Peptic ulceration, gastritis, increased appetite. * **Immune:** Increased susceptibility to secondary infections. * **Dermatologic:** Impaired wound healing, thin skin, acne. ## Key Drug Interactions * **Anticoagulants (Warfarin):** May decrease or increase anticoagulant effect; monitor INR. * **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Carbamazepine):** Decrease dexamethasone levels; may require dose increase. * **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding. * **Antidiabetic agents:** Dexamethasone antagonizes hypoglycemic effects; requires increased monitoring and possible dose adjustments for insulin/oral agents. ## Monitoring * Blood glucose levels (especially in patients with diabetes). * Signs of infection or occult bleeding. * Blood pressure and electrolytes (potassium). * Neurologic status (for cerebral edema). * Growth and development (in long-term pediatric use). ## Clinical Pearls * **Potency:** Dexamethasone is approximately 20–30 times more potent than hydrocortisone. * **Long-acting:** It does not have mineralocorticoid properties, making it preferred when fluid retention is a concern, though it still risks significant metabolic dysregulation. * **Administration:** IV push is typically administered over 1–5 minutes. * **Tapering:** Patients on prolonged high-dose therapy must be tapered to prevent steroid withdrawal/adrenal crisis. *** *Disclaimer: This information is for educational purposes only. Dosing, contraindications, and drug interactions change. Always consult the latest institutional protocols, current package inserts, and evidence-based clinical resources before prescribing or administering medication.*